1. Home
  2. EVGN vs BCDA Comparison

EVGN vs BCDA Comparison

Compare EVGN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVGN
  • BCDA
  • Stock Information
  • Founded
  • EVGN 1999
  • BCDA N/A
  • Country
  • EVGN Israel
  • BCDA United States
  • Employees
  • EVGN N/A
  • BCDA N/A
  • Industry
  • EVGN Agricultural Chemicals
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVGN Industrials
  • BCDA Health Care
  • Exchange
  • EVGN Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • EVGN 11.6M
  • BCDA 11.3M
  • IPO Year
  • EVGN N/A
  • BCDA N/A
  • Fundamental
  • Price
  • EVGN $1.24
  • BCDA $2.04
  • Analyst Decision
  • EVGN Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • EVGN 1
  • BCDA 1
  • Target Price
  • EVGN $3.50
  • BCDA $25.00
  • AVG Volume (30 Days)
  • EVGN 55.7K
  • BCDA 74.5K
  • Earning Date
  • EVGN 08-19-2025
  • BCDA 08-11-2025
  • Dividend Yield
  • EVGN N/A
  • BCDA N/A
  • EPS Growth
  • EVGN N/A
  • BCDA N/A
  • EPS
  • EVGN N/A
  • BCDA N/A
  • Revenue
  • EVGN $9,444,000.00
  • BCDA N/A
  • Revenue This Year
  • EVGN N/A
  • BCDA N/A
  • Revenue Next Year
  • EVGN $63.64
  • BCDA N/A
  • P/E Ratio
  • EVGN N/A
  • BCDA N/A
  • Revenue Growth
  • EVGN N/A
  • BCDA N/A
  • 52 Week Low
  • EVGN $0.95
  • BCDA $1.63
  • 52 Week High
  • EVGN $3.35
  • BCDA $3.26
  • Technical
  • Relative Strength Index (RSI)
  • EVGN 46.32
  • BCDA 55.51
  • Support Level
  • EVGN $1.26
  • BCDA $1.90
  • Resistance Level
  • EVGN $1.33
  • BCDA $1.99
  • Average True Range (ATR)
  • EVGN 0.07
  • BCDA 0.08
  • MACD
  • EVGN -0.00
  • BCDA 0.03
  • Stochastic Oscillator
  • EVGN 20.48
  • BCDA 96.15

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: